Lan, C., Lu, H., Zhou, L., Liao, K., Liu, J., Xie, Z., . . . Huang, X. (2024). Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study. Cancer Communications, 44(6), 654. https://doi.org/10.1002/cac2.12547
Chicago-referens (17:e uppl.)Lan, Chunyan, et al. "Long‐term Survival Outcomes and Immune Checkpoint Inhibitor Retreatment in Patients with Advanced Cervical Cancer Treated with Camrelizumab Plus Apatinib in the Phase II CLAP Study." Cancer Communications 44, no. 6 (2024): 654. https://doi.org/10.1002/cac2.12547.
MLA-referens (9:e uppl.)Lan, Chunyan, et al. "Long‐term Survival Outcomes and Immune Checkpoint Inhibitor Retreatment in Patients with Advanced Cervical Cancer Treated with Camrelizumab Plus Apatinib in the Phase II CLAP Study." Cancer Communications, vol. 44, no. 6, 2024, p. 654, https://doi.org/10.1002/cac2.12547.
